CoChat

Regulating Artificial Intelligence for a Successful Pathology Future

Open access
Allen, Timothy Craig · 2019 · Archives of Pathology & Laboratory Medicine
Cited by 43

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Artificial intelligence (AI), a set of techniques aimed at approximating some aspect of human cognition using machines,1 promises to provide pathologists a tool to improve inefficiencies and inaccuracies in diagnosis and laboratory testing, and to facilitate an anticipated decreasing number of pathologists' ability to serve an increasing number of patients with timely diagnoses, even as those diagnoses exhibit an increasingly complicated molecular complexity.2–4 Pathology has long examined the use of AI in pathologic diagnosis5 and is already using AI. Papanicolaou test imaging, approved by the US Food and Drug Administration (FDA) for screening purposes, is now fully, if not widely, used.6,7 Other areas of cytopathology are investigating the use of AI for diagnosis,8 and AI will undoubtedly play a strong and central role in its continuing progress toward becoming fully automated.9–11 Artificial intelligence in pathology promises to outperform human beings in their assessment of the specific characteristics necessary for pathologic and radiologic diagnosis.9,12 Despite the initial hysteria,13–16 it is now clear that AI will be, at least for the foreseeable future, a tool for pathologists, not a replacement for pathologists, and it is evident that although AI's use will fundamentally alter pathology practice, it is perhaps pathologists' greatest opportunity to invest themselves more fully in their patients' care.3,7 Pathologists' success with AI, however, will depend to a large degree on the successful implementation of efficient AI governance and regulation.Current regulation of AI technology, still relatively nascent, includes some basic regulatory frameworks from the FDA.17,18 Currently, the Clinical Laboratory Improvement Amendments of 1988 (CLIA) has requirements for the use of artificial intelligence in pathology. Under CLIA, laboratory use of artificial intelligence is limited to developing algorithms prior to validation and implementation. Changing the rules of test performance after validation and implementation is generally not allowed without revalidation. Medical societies and other groups have also weighed in on AI regulation. The American Medical Association (AMA) has also examined artificial intelligence in health care, promoting the interaction of physicians with the federal regulatory regime, emphasizing patient privacy and confidentiality issues, and supporting an AMA policy regarding AI that can be continuously refined.19 Further, the Royal Australian and New Zealand College of Radiologists has drafted some ethical principles for AI in health care,20 and the Center for Data Innovation, a data, technology, and public policy think tank, has suggested that the United States develop a national strategy around artificial intelligence to maximize its value.21Mature discussion and strategizing of AI regulation is increasingly needed. It is evident that AI will increasingly be necessary to interpret the world, and will be integral to social, political, and business environments, making decisions for human beings.22 Yet, the development of AI, broadly speaking, has occurred substantially outside any regulatory environment.23 There are few state laws, essentially no court cases, and very little legal scholarship addressing AI regulation.23 The lack of much-needed legal regulatory scholarly examination and regulatory guidance should not be surprising. Artificial intelligence development, marketing, and use do not fit the traditional regulatory environment, which has long provided robust solutions for long-established regulatory needs, such as patent, trademark, and copyright law, tort liability, and research and development oversight.23The need for regulation of AI will continue to grow as it becomes increasingly integral to numerous technologies, including health care technology, with which people are progressively interacting. Yet effective and sufficient AI governance is likely to be stubbornly difficult to establish. Beyond considerations of responsibility and accountability for actions taken by or with the input of AI, governance will require deep and novel considerations of normative explanations of AI applications, implementation scenarios, and ethical standards.22 Further, AI's risks do not fit the typical regulatory paradigms. It often requires little infrastructure, and it contains components not designed in a coordinated manner, assembled by numerous, widespread people with little personal interaction, with the development and results usually opaque to outsiders. As such, potential harmful features, which could be regulated away or diminished, are not easily identified.23 Additionally, complicating research and development issues, collective issues that do not directly involve individual AI systems, and policymakers' general lack of specialized knowledge of AI development make governance before AI implementation extremely complicated, with little ability to control unforeseeable consequenc

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5858/arpa.2019-0229-ed

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 43

Metadata

Authors
Allen, T. C.
Venue
Archives of Pathology & Laboratory Medicine
Published
2019-07-03
Volume
143
Issue
10
Pages
1175-1179
ISSN
  • 0003-9985 (ISSN-L)
  • 1543-2165
OpenAlex
W2954646778
Cited by
43
References
3
FWCI
1.56
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Regulating Artificial Intelligence for a Successful Pathology Future. https://app.cochat.ai/papers/10.5858/arpa.2019-0229-ed
The paper
Allen, T. C. (2019). Regulating Artificial Intelligence for a Successful Pathology Future. Archives of Pathology & Laboratory Medicine. https://doi.org/10.5858/arpa.2019-0229-ed

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.